Accentuated hyperparathyroidism in type II Bartter syndrome.

Area of Science:

• Nephrology
• Endocrinology
• Genetics

Background:

• Bartter syndrome (BS) can involve hypercalciuria, but significant parathyroid hormone (PTH) abnormalities are not well-documented.
• This study investigates distinct subtypes of Bartter syndrome, focusing on potential PTH-related differences.

Purpose of the Study:

• To compare clinical and laboratory findings between ROMK-deficient type II BS (BS-II) and Barttin-deficient type IV BS (BS-IV).
• To investigate potential parathyroid hormone (PTH) resistance in Bartter syndrome subtypes.

Main Methods:

• Clinical and laboratory data from 14 patients with BS-II and 20 patients with BS-IV were analyzed.
• Key parameters included serum electrolytes, PTH, phosphate, estimated glomerular filtration rate (eGFR), and urine calcium/creatinine ratios.

Main Results:

• BS-II patients exhibited significantly higher PTH levels (160.6 vs. 92.5 pg/ml) and increased serum phosphate (Pi)-SDS compared to BS-IV patients.
• The fractional renal excretion of phosphate was higher in BS-II, indicating altered phosphate handling.
• Nephrocalcinosis was more prevalent in BS-II (100%) than in BS-IV (16%).

Conclusions:

• Elevated PTH, serum Pi, and urinary phosphate reabsorption threshold in BS-II suggest PTH resistance.
• This resistance may be a compensatory mechanism for severe, long-standing hypercalciuria, contributing to higher nephrocalcinosis rates in BS-II.